Drug Profile
TBA 354
Alternative Names: TBA-354Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Global Alliance for TB Drug Development; University of Auckland
- Developer Global Alliance for TB Drug Development
- Class Antituberculars; Nitroimidazoles; Oxazines; Pyridines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for phase-I development in Tuberculosis(In volunteers) in USA (PO, Suspension)
- 19 Nov 2015 Global Alliance for TB Drug Development plans a phase I trial in Healthy volunteers in USA (NCT02606214)
- 01 Jan 2015 Phase-I clinical trials in Tuberculosis (In volunteers) in USA (PO)